Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in XXXX -associated @entity409 .

@entity1 @entity844 @entity82 @entity27982 @entity409 @entity3147 @entity1460
Home @entity3147 ( @entity3147 ) is associated with many complications including severe @entity409 . Commercial   -6 @entity844 - @entity1460 based-lipid emulsions in @entity3147 may mediate long term @entity3147 associate @entity409 (PNALD) whereas   -3-fish oil parenteral emulsions have shown to reverse PNALD in @entity1 . However, its clinical effectiveness in adults has been scarcely reported. In this work, we study the role of @entity1460 and fish oil lipid commercial emulsions on inflammatory and profibrotic liver markers in adults with long term PNALD and in in vitro cellular models. Inflammatory and profibrotic markers were measured in serum of ten adults with long term PNALD and in culture supernatants of monocytes. Liver epithelial to mesenchymal transition (EMT) was induced by transforming growth factor beta 1 (TGFb1) to evaluate in vitro liver @entity82 . Omegaven  , a 100% fish oil commercial emulsion, was infused during four months in two @entity1 with severe long term PNALD reversing, at the first month, the inflammatory, profibrotic and clinical parameters of PNALD. The effect was maintained during the treatment course but impaired when conventional lipid emulsions were reintroduced. The other @entity1 under chronic @entity1460 oil-based @entity3147 showed elevated inflammatory and profibrotic parameters. In vitro @entity1 monocytes stimulated with lipopolysaccharide induced a strong inflammatory response that was suppressed by @entity27982  , but increased by @entity1460 emulsions. In other experiments, TGFb1 induced EMT that was suppressed by Omegaven   and enhanced by @entity1460 oil lipid emulsions. Omegaven   improves clinical, anti-inflammatory and anti-fibrotic parameters in adults with long-term home PNALD.
